Category: News & Events

Pregnancy History is Critical in Our Female Patients

Announcing a new article publication for Cardiovascular Innovations and Applications journal.  Cardiovascular disease remains the leading cause of death amongst women. Pregnancy reflects a time of significant cardiovascular stress during a woman’s life, with associated significant hemodynamic changes that can exacerbate underlying cardiovascular disease (CVD) or un-mask previously unknown CVD conditions. Women are now advancing in age prior to conception and entering childbearing years with a higher incidence of CVD conditions and risk factors. In turn, pregnancy complications and other reproductive conditions can pre-dispose to future cardiovascular risk. Thus, it is important to recognize pregnancy and reproductive history, as this can also serve as an important window into future cardiovascular disease risk.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2024.0014

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Ki Park. Pregnancy History is Critical in Our Female Patients. CVIA. 2024. Vol. 9(1). DOI: 10.15212/CVIA.2024.0014

Loading

A 24-Week, Multi-Center, Randomized, Open-Label Clinical Trial Comparing the Effects of Xuezhikang and Atorvastatin on Glucose Metabolism in Patients with Dyslipidemia and Prediabetes (XTREME Study): Design of the Study Protocol

Announcing a new article publication for Cardiovascular Innovations and Applications journal.   Statins, a first-line therapeutic option for atherosclerotic cardiovascular disease (ASCVD), have prompted concerns regarding dysglycemia and diabetes, thus posing a dilemma in treating patients with prediabetes. Xuezhikang (XZK) decreases blood cholesterol levels without affecting glucose metabolism, and may serve as a potential substitute.

The XTREME study is a prospective, randomized, open-label, multi-center trial evaluating whether XZK 1200 mg/d, compared with atorvastatin 20 mg/d, has favorable effects on HbA1c levels after 24 weeks of treatment in patients with dyslipidemia and prediabetes. After a 1-week run-in period for adherence assessment, the study will randomly assign (1:1) 392 patients meeting the protocol inclusion criteria to one of two treatment groups: an experimental group (XZK 1200 mg/day) or a control group (atorvastatin 20 mg/day). All participants will be recruited from approximately 20 Chinese medical centers. The primary endpoint will be change in HbA1c level from baseline to 24 weeks, or before anti-diabetic therapy initiation within 24 weeks. The key secondary outcomes will include other biomarkers reflecting blood glucose or lipid metabolism.

Delaying diabetes is desirable for individuals with prediabetes. The XTREME trial presents a unique opportunity to demonstrate whether XZK might provide an alternative to statins for patients with dyslipidemia and prediabetes.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2024.0010

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Lan Fu, Yiqun Zhang and Xin Du et al. A 24-Week, Multi-Center, Randomized, Open-Label Clinical Trial Comparing the Effects of Xuezhikang and Atorvastatin on Glucose Metabolism in Patients with Dyslipidemia and Prediabetes (XTREME Study): Design of the Study Protocol. CVIA. 2024. Vol. 9(1). DOI: 10.15212/CVIA.2024.0010

Loading

Identification of Potential Targets of Stress Cardiomyopathy by a Machine Learning Algorithm

Announcing a new article publication for Cardiovascular Innovations and Applications journal.  Stress cardiomyopathy (SCM) is a reversible, self-limiting condition that manifests as left ventricular insufficiency. The incidence of stress cardiomyopathy has increased because of increasing mental and social stress, but the exact pathophysiological mechanisms remain unclear.

To elucidate the critical molecules in the pathogenesis of SCM and the functional changes that they mediate, data for a healthy control group and stress cardiomyopathy (SCM) group was downloaded from the Gene Expression Omnibus database, differential analysis was performed, and the results of GO and KEGG enrichment analysis was analysed to describe SCM-associated genes and functions. Lasso, random forest, SVM-RFM, and Friends analysis were used to screen hub genes; CIBERSORT and MCPcounter were used to explore the relationship between SCM and immunity; and an animal model of SCM was constructed to conduct bidirectional verification of the obtained results.

In total, 21 samples (6 healthy, 15 SCM) were used in this study. Overall, 39 DEGs (absolute fold change ≥ 1; P < 0.05), including 23 upregulated and 16 downregulated genes in SCM, were extracted. Three common hub genes (PLAT, SEMA6B, and CRP) were finally screened. It was further confirmed that functional changes in SCM were concentrated in immunity and coagulation functions.

Three key genes (PLAT, SEMA6B, and CRP) in SCM were identified by machine learning, and the major functional changes leading to SCM, and relationships of SCM with immunity, were identified.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2024.0011

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Xuexin Jin, Xuanrui Ji and Hongpeng Yin et al. Identification of Potential Targets of Stress Cardiomyopathy by a Machine Learning Algorithm. CVIA. 2024. Vol. 9(1). DOI: 10.15212/CVIA.2024.0011

Loading

Cardiovascular Innovations and Applications now indexed by SCOPUS

We are happy to announce this very good news to all authors, editors, reviewers and readers.scopus

Cardiovascular Innovations and Applications will be indexed by SCOPUS from February 26th, 2024. The bibliographic database managed by Elsevier covers high-ranking peer-reviewed journals in the technical, medical and social sciences.

On this occasion, congratulations to Professor Jamie B. Conti and Professor Jianzeng Dong, Cardiovascular Innovations and Applications editorial team and all contributors, reviewers, readers and editorial assistants for making it happen.

This news means that even more researchers and scientists will get access to high-quality research papers published in Cardiovascular Innovations and Applications.

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Loading

IL-6 and D-dimer Levels at Admission Predict Cardiac Injury and Early Mortality during SARS-CoV-2 Infection

Announcing a new article publication for Cardiovascular Innovations and Applications journal. The activation of immune and thrombotic biomarkers at admission, and their ability to predict cardiac injury and mortality patterns in COVID-19, remains unclear.

This retrospective cohort study included 170 patients with COVID-19 with cardiac injury at the time of admission to Tongji Hospital in Wuhan between January 29, 2020, and March 8, 2020. The temporal evolution of inflammatory cytokines, coagulation markers, clinical treatment, and mortality were analyzed. Continuous variables are expressed as median (interquartile range).

(more…)

Loading

Protocol for a Single-Center Randomized Controlled Trial of Percutaneous Coronary Intervention Via Distal Transradial Access Versus Transradial Access

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Although transradial access (TRA) has become the main vascular access for coronary intervention, its high radial artery occlusion rate limits its application in some patients. Studies have shown that compared with TRA, distal transradial access (dTRA) with the snuffbox area or the Hegu acupoint area as the puncture point significantly decreases the incidence of radial artery occlusion. However, no randomized controlled study has confirmed the safety and efficacy of coronary artery intervention via dTRA in China.

This single-center, prospective, randomized controlled, superiority open-label study will enroll 428 consecutive patients with coronary heart disease undergoing percutaneous coronary intervention as the study population. After preoperative evaluation, the participants will be randomly divided into a study group (dTRA) and control group (TRA) in a 1:1 ratio. The primary endpoint (radial artery occlusion at 24 hours after operation) and secondary endpoint events will be evaluated and recorded.

This study has been registered in the Chinese Clinical Trial Registry (registration number: ChiCTR2300073902).

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2024.0015

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Minghao Liu, Huanhuan Wang and Lijian Gao et al. Protocol for a Single-Center Randomized Controlled Trial of Percutaneous Coronary Intervention Via Distal Transradial Access Versus Transradial Access. CVIA. 2024. Vol. 9(1). DOI: 10.15212/CVIA.2024.0015

Loading

Rheumatoid Arthritis and Risk of Atrial Fibrillation: Results from Pooled Cohort Studies and Mendelian Randomization Analysis

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Observational research has indicated that individuals diagnosed with rheumatoid arthritis (RA) have an elevated likelihood of developing atrial fibrillation (AF). The authors of this article performed meta-analysis and Mendelian randomization (MR) analysis to explore the correlation and potential causal relationship between RA and AF. PubMed, Embase, and Web of Science were searched for cohort studies comparing AF risk among participants with and without RA. Quantitative synthesis of the adjusted risk ratio (RR) or hazard ratio was performed with the random-effects model. RA and AF were studied with two-sample MR analysis with the random-effects inverse variance weighted method. Patients with RA had a higher risk of AF than participants without RA [RR = 1.32, 95% confidence interval (CI): 1.23–1.43, P < 0.0001]. Genetically predicted RA was not associated with a significantly elevated risk of AF (odds ratio = 1.009, 95% CI: 0.986–1.032, P = 0.449). After adjustment for confounding factors in multifactorial MR, RA and AF still showed no correlation. Sensitivity analyses yielded similar results, thus indicating the robustness of the causal association. Overall, RA was associated with elevated risk of AF in this meta-analysis. However, genetically predicted RA may not be causal.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2024.0006

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Qiyuan Song, Luxiang Shang and Yujiao Zhang et al. Rheumatoid Arthritis and Risk of Atrial Fibrillation: Results from Pooled Cohort Studies and Mendelian Randomization Analysis. CVIA. 2024. Vol. 9(1). DOI: 10.15212/CVIA.2024.0006

Loading

Prognostic Value of Optical Flow Ratio among Patients with Coronary Artery Disease after Percutaneous Coronary Treatment: A Hospital-Based Retrospective Cohort Investigation

Announcing a new article publication for Cardiovascular Innovations and Applications journal.  The goal of this study was to examine the prognostic performance of optical flow ratio (OFR) among patients with coronary artery disease (CAD) after percutaneous coronary intervention (PCI).

Patients with CAD undergoing optical coherence tomography (OCT)-directed PCI were recruited between January 2019 and June 2021 for a single-center, hospital-based, retrospective cohort investigation. The link between post-PCI OFR and major adverse cardiovascular events (MACE) was assessed via multivariate Cox regression analysis.

Receiver operating characteristic analysis revealed that the best post-PCI OFR threshold for MACE was 0.91, and introduction of OFR into the baseline profile and OCT results markedly enhanced MACE identification after PCI. On the basis of survival curves, patients with OFR ≤0.91 (P < 0.001) and thin-cap fibroatheroma (TCFA) (P = 0.007) exhibited higher MACE incidence, and myocardial infarction (MI) incidence was considerably greater among patients with OFR ≤0.91 (P < 0.001), compared with OFR >0.91. Multivariate Cox regression analysis suggested that OFR ≤0.91 (hazard ratio [HR]: 3.60; 95% confidence interval [CI]: 1.24–10.44; P = 0.019), and TCFA (HR: 3.63; 95% CI: 1.42–9.20; P = 0.007) were independent risk factors for MACE, and OFR ≤0.91 was independently associated with MI (HR: 14.64; 95% CI: 3.27–65.54; P < 0.001).

OFR after PCI is an independent MACE bio-indicator among patients with CAD. Adding OFR to post-PCI OCT results may potentially enhance MACE prediction.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2024.0012

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Chuliang Hong, Sicheng Chen and Tianyu Hu et al. Prognostic Value of Optical Flow Ratio among Patients with Coronary Artery Disease after Percutaneous Coronary Treatment: A Hospital-Based Retrospective Cohort Investigation. CVIA. 2024. Vol. 9(1). DOI: 10.15212/CVIA.2024.0012

Loading

Overview of Postural Orthostatic Tachycardia Syndrome (POTS) for General Cardiologists

Announcing a new article publication for Cardiovascular Innovations and Applications journal.  Postural tachycardia syndrome (POTS) is a chronic autonomic disorder characterized by excessive heart rate elevation upon standing or head-up tilt, in the absence of orthostatic hypotension. This debilitating condition affects primarily young to middle-aged individuals, particularly women, and substantially influences quality of life. The main presenting symptoms are lightheadedness, palpitations, exercise intolerance, and cognitive impairment. POTS is of particular importance to cardiologists, given its prominent cardiovascular symptoms. The diagnostic criteria for POTS include a sustained heart rate increase of more than 30 beats per minute upon standing or head-up tilt; symptoms of orthostatic intolerance lasting at least 3 months; and exclusion of other causes. The exact etiology of POTS is unknown, but multiple possible etiologies leading to a similar clinical phenotype have been proposed. Early intervention and appropriate management can improve symptoms. Treatment strategies include lifestyle modifications, pharmacotherapy, and tailored conditioning programs. Non-pharmacologic options are the first line treatment. Prognosis varies widely: POTS can be a temporary condition for some individuals but a chronic and debilitating condition for others. Further research is necessary to elucidate the pathophysiology and optimize treatment strategies for this condition.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0098

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Ali Nassereddin, Ethan Kramer and Artur Fedorowski et al. Overview of Postural Orthostatic Tachycardia Syndrome (POTS) for General Cardiologists. CVIA. 2024. Vol. 9(1). DOI: 10.15212/CVIA.2023.0098

Loading

Clinical Features and Etiology of Recurrent Hypertension after Adrenalectomy

Announcing a new article publication for Cardiovascular Innovations and Applications journal.

Patients who undergo adrenalectomy for unilateral primary aldosteronism (PA) may still develop post-surgery hypertension; however, the clinical characteristics and etiology of patients developing recurrent hypertension after adrenalectomy are unclear. We analyzed the records of 43 patients with recurrent elevated blood pressure after adrenalectomy, who were treated at our center. Standard routine clinical screening workup was used to identify the cause of recurrent hypertension. Causes of recurrent hypertension after adrenalectomy included essential hypertension, primary aldosteronism, obstructive sleep apnea, renal artery stenosis, and Takayasu arteritis. Before adrenalectomy, 39.5% of patients were diagnosed with confirmed or suspected PA, primarily through CT imaging.

Adrenal venous sampling (AVS) tests were not conducted on any patients, and 72.1% patients underwent partial adrenalectomy. Among all patients, elevated blood pressure was observed in 44.2% immediately post-operation, 18.6% within 1 month, 16.3% in 1–6 months, and 20.9% >6 months after operation. Most patients had hypertension of grade 2 and above. Standard endocrine functional assessment and AVS tests should be performed before adrenalectomy to ensure more accurate diagnosis and favorable post-operative outcomes. Additionally, individuals often develop essential hypertension regardless of past adrenal disease.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0092

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Xilan Dong, Qianhui Ling and Jin Bian et al. Clinical Features and Etiology of Recurrent Hypertension after Adrenalectomy. CVIA. 2024. Vol. 9(1). DOI: 10.15212/CVIA.2023.0092

Loading